```
CF PharmTech, Inc. is a specialty pharmaceutical company founded in 2007 in China, focusing on the development and manufacturing of inhalation products for respiratory diseases. Their product range includes HFA-based metered dose inhalers, nasal spray, nebulized, and dry powder products. The company is led by a team of experienced scientists and executives with a combined 50 years of experience in the American pharmaceutical industry.
The latest investment in CF PharmTech, Inc. was a substantial CNY360.00M Series F round, which took place on 01 July 2020. The investment was supported by a consortium of prominent investors including Passion Capital, BioTrack Capital, SAIC Capital Management, YuanMing Capital, Peter Watson Investments, CICC Qichen, GP M&A Fund, and CICC Qide.
CF PharmTech, Inc. operates in the Health Care, Manufacturing, and Pharmaceutical industries, with a mission to improve and reduce the cost of medications for the global market.
```| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series F | CNY360.00M | 9 |
|
01 Jul 2020 |
| Series E | CNY630.00M | 1 | CR-CP Life Science Fund | 01 Jan 2020 |
| Venture Round | Unknown | - | 01 Jan 2018 | |
| Series D | $65.00M | - | 28 Aug 2017 |
No recent news or press coverage available for CF PharmTech, Inc..
We care about your data, and we'd love to use cookies make your experience better.
